Risk of Subclinical Atherosclerosis in Patients with Antiphospholipid Syndrome and Subjects With Antiphospholipid Antibody Positivity: A Systematic Review and Meta-analysis - PubMed

Review

Risk of Subclinical Atherosclerosis in Patients with Antiphospholipid Syndrome and Subjects With Antiphospholipid Antibody Positivity: A Systematic Review and Meta-analysis

Paschalis Karakasis et al. Curr Probl Cardiol. 2023 Jun.

Abstract

Currently, the guidelines for the prevention of atherosclerosis in patients with antiphospholipid syndrome (APS) do not differ substantially from those in the general population. We aimed to assess the risk of subclinical atherosclerosis in patients with APS and subjects with antiphospholipid antibody (aPL) positivity. Systematic literature search was conducted through Medline and Scopus until January 2023. Random effects meta-analyses were performed to examine the differences in markers of subclinical atherosclerosis between APS patients, subjects positive for aPLs and healthy controls. Patients with APS had significantly higher values of common carotid artery (CCA) intima-media thickness (IMT) (MD = 0.07 mm; P < 0.0001), internal carotid artery IMT (MD = 0.06 mm; P < 0.01), carotid bifurcation IMT (MD = 0.14 mm; P < 0.01) and were more frequently diagnosed with atherosclerotic plaques compared to controls (OR = 3.73; P < 0.01). Similarly, APS patients showed a decreased flow and nitrate-mediated dilation (MD = -4.52 %; <0.01, MD = -1.25 %; P < 0.05, respectively). Interestingly, comparable were the results for subjects with aPL positivity, who had higher CCA-IMT (MD = 0.06 mm; P < 0.01) and higher prevalence of atherosclerotic plaques (OR = 2.59; P = 0.08) compared to controls. Sensitivity analysis conducted on primary APS patients revealed that the risk of atherosclerosis is associated with APS per se and is not exclusively driven by other underlying conditions. Patients with APS and subjects with aPLs have an increased risk of subclinical atherosclerosis and require early and disease-specific prevention of atherosclerosis.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

• Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: A cross-sectional study.

  Di Minno MND, Emmi G, Ambrosino P, Scalera A, Tufano A, Cafaro G, Peluso R, Bettiol A, Di Scala G, Silvestri E, Prisco D. Di Minno MND, et al. Int J Cardiol. 2019 Jan 1;274:1-6. doi: 10.1016/j.ijcard.2018.06.010. Epub 2018 Jun 5. Int J Cardiol. 2019. PMID: 30454720

• Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies.

  Ambrosino P, Lupoli R, Di Minno A, Iervolino S, Peluso R, Di Minno MN. Ambrosino P, et al. Ann Med. 2014 Dec;46(8):693-702. doi: 10.3109/07853890.2014.959559. Epub 2014 Oct 13. Ann Med. 2014. PMID: 25307359 Review.

• Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis.

  Bettiol A, Emmi G, Finocchi M, Silvestri E, Urban ML, Mattioli I, Scalera A, Lupoli R, Vannacci A, Di Minno MND, Prisco D. Bettiol A, et al. Rheumatology (Oxford). 2020 Dec 1;59(12):3709-3716. doi: 10.1093/rheumatology/keaa116. Rheumatology (Oxford). 2020. PMID: 32388557

• Reduced plasma fibrin clot permeability and susceptibility to fibrinolysis are associated with increased intima-media thickness in patients with primary antiphospholipid syndrome.

  Asztabski M, Wypasek E, Ząbczyk M, Undas A. Asztabski M, et al. Thromb Res. 2014 Nov;134(5):945-51. doi: 10.1016/j.thromres.2014.07.042. Epub 2014 Aug 21. Thromb Res. 2014. PMID: 25194881

• Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies.

  Ambrosino P, Lupoli R, Di Minno A, Tasso M, Peluso R, Di Minno MN. Ambrosino P, et al. Thromb Haemost. 2015 May;113(5):916-30. doi: 10.1160/TH14-11-0921. Epub 2015 Feb 26. Thromb Haemost. 2015. PMID: 25716931 Review.

Cited by

• Cardiovascular risk assessment in patients with antiphospholipid syndrome: a cross-sectional performance analysis of nine clinical risk prediction tools.

  Drosos GC, Konstantonis G, Sfikakis PP, Tektonidou MG. Drosos GC, et al. RMD Open. 2023 Nov 27;9(4):e003601. doi: 10.1136/rmdopen-2023-003601. RMD Open. 2023. PMID: 38016710 Free PMC article.

• Antiphospholipid Syndrome: Insights into Molecular Mechanisms and Clinical Manifestations.

  Celia AI, Galli M, Mancuso S, Alessandri C, Frati G, Sciarretta S, Conti F. Celia AI, et al. J Clin Med. 2024 Jul 18;13(14):4191. doi: 10.3390/jcm13144191. J Clin Med. 2024. PMID: 39064231 Free PMC article. Review.

• Autoimmune diseases and cardiovascular risk: Mendelian randomization analysis for the impact of 19 autoimmune diseases on 14 cardiovascular conditions.

  Bao Y, Gu L, Chen J, Wang H, Wang Z, Wang H, Wang S, Wang L. Bao Y, et al. J Transl Autoimmun. 2024 Nov 1;9:100259. doi: 10.1016/j.jtauto.2024.100259. eCollection 2024 Dec. J Transl Autoimmun. 2024. PMID: 39554254 Free PMC article.

• Application of EULAR and European Society of Cardiology recommendations with regard to blood pressure and lipid management in antiphospholipid syndrome.

  Drosos GC, Konstantonis G, Sfikakis PP, Tektonidou MG. Drosos GC, et al. RMD Open. 2023 Aug;9(3):e003326. doi: 10.1136/rmdopen-2023-003326. RMD Open. 2023. PMID: 37558493 Free PMC article.

• Quantitative and Qualitative Characteristics of Atherosclerotic Plaques on Carotid Arteries in Patients with Antiphospholipid Syndrome: The Role of MDCT Angiography.

  Saponjski J, Stojanovich L, Stanisavljevic N, Djokovic A, Vojinovic R, Kocic S, Nikolic S, Matic P, Filipovic B, Djulejic V, Colovic V, Bogosavljevic N, Aleksandric D, Kostic D, Brkic Georgijevski B, Misovic M, Colic N, Saponjski D. Saponjski J, et al. Diseases. 2023 Sep 28;11(4):131. doi: 10.3390/diseases11040131. Diseases. 2023. PMID: 37873775 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal